Key result
Intramuscular AAV-TetON-vIL10 plus doxycycline reduces collagen-induced arthritis incidence and severity in mice vs controls.
Why the study?
Adeno-associated viruses offer potential for cytokine gene transfer in rheumatoid arthritis with long-term expression and regulated therapeutic gene control, but their efficacy and regulation in RA models needed assessment.
Does AAV-TetON-vIL10 gene transfer reduce arthritis severity in a mouse model of rheumatoid arthritis?
Does AAV-TetON-vIL10 gene transfer reduce arthritis severity in a mouse model of rheumatoid arthritis?
AAV-mediated, tetracycline-inducible vIL-10 gene transfer provides controlled therapeutic efficacy in a mouse model of rheumatoid arthritis.
Answers are grounded in this paper and cite their sources.
Supports inducible vIL-10 gene therapy in arthritis models; leaves open translation to human rheumatoid arthritis.
The adeno-associated viruses (AAV) offer new perspectives for cytokine gene transfer in rheumatoid arthritis (RA) because they are nonpathogenic and allow long-term transgene expression in vivo. Moreover, the use of a tetracycline-inducible promoter allows regulation of therapeutic gene expression. This study assessed the potential long-term gene regulation of a recombinant AAV vector expressing viral interleukin-10 (vIL-10) in human rheumatoid synovium and the therapeutic efficiency in a mouse model of RA. We constructed a recombinant AAV vector in which the transcription of vIL-10 cDNA is controlled by the TetON system. Transduction of human primary RA synovial cells with AAV-tetON-vIL10 conferred in vitro controlled vIL-10 expression. After intramuscular injection, both incidence and severity of collagen-induced arthritis were significantly reduced at macroscopic, radiological, and histological levels in the group of DBA1 mice treated with AAV-TetON-vIL10 vector plus doxycycline after immunization and boosting compared to control groups. When coinjecting two separate AAV vectors, one encoding the inducible vIL-10 and the other the transcriptional activator, a 10 times excess of the transactivator vector dose allowed efficient control of vIL-10 secretion by doxycycline administration or withdrawal, over an 8-week period. Our results supported, for the first time, the utility of AAV-tetON-vIL10 as a therapeutic tool for gene therapy in RA.
No takes yet. Share an insight, caveat, or question.
Apparailly et al. (2002) studied Rheumatoid arthritis (experimental). AAV-TetON-vIL10 vector plus doxycycline vs. Control groups was evaluated on Incidence and severity of collagen-induced arthritis at macroscopic, radiological, and histological levels. Intramuscular injection of AAV-TetON-vIL10 vector plus doxycycline significantly reduced the incidence and severity of collagen-induced arthritis in DBA1 mice compared to control groups.
Synapse has enriched 10 related papers. Consider them for comparative context: